Background {#Sec1}
==========

Frailty is considered a condition in older people characterised by a loss of physiological reserve, which causes increased clinical vulnerability \[[@CR1]--[@CR3]\].

Frail older adults are vulnerable to changes in their health status to the extent that any assault on the body, such as a minor infection, or a fall can have disproportionately negative outcomes \[[@CR4], [@CR5]\]. A measure of individual levels of frailty is needed to guide decision making, for example, when clinicians are considering treatment options in the aftermath of an acute episode or event, particularly as evidence suggests that frailty may be modifiable \[[@CR6]\]. Identifying frail older adults would, therefore, help target specific health interventions and services needed to improve outcomes for this vulnerable cohort \[[@CR1]\].

While there is a strong relationship between frailty and chronological age, frailty status is only one of many important factors that determine outcome; others include personal resources, social support and environmental factors, illness acuity and severity \[[@CR7]\].

The measure of frailty has been considered using a phenotype model whereby the presence or absence of a pre defined set of five specific signs and symptoms are used to measure the degree of frailty of a specific individual \[[@CR8]\]. Alternatively, frailty has been viewed from the perspective of an accumulation of deficits in the form of a frailty index \[[@CR9]\]. A robust frailty index requires a significant number of individual items which are utilised to record deficit accumulation, and which are recorded as a score or index. This can also then be monitored in subsequent assessments to record the effectiveness or otherwise of specific interventions aimed at reducing an individual's level of frailty \[[@CR10]\].

A frailty index was recently developed using a standardised assessment of patients in acute care in Australia: the interRAI acute care (AC) instrument \[[@CR6]\]. Using the methodology of Searle et al., 2008, \[[@CR11]\] specific variables, common to all interRAI instruments, were identified within the assessment as potential health deficits. The interRAI-AC assessment used in that study is part of a validated interRAI suite of assessment tools, which also includes the Minimum Dataset-Homecare (MDS-HC) assessment \[[@CR12]--[@CR14]\]. The different interRAI tools are specifically designed so that core questions are the same and as a consequence a person's health status can be tracked across different health settings using the appropriate interRAI assessment \[[@CR15]\]. The MDS-HC assessment (recently updated and renamed as the interRAI Homecare assessment) is used in New Zealand to aid care of all older people living at home, who require publicly-funded community support or assessment for government-funded long-term residential care \[[@CR16]\].

The MDS-HC has been demonstrated to be a valid and reliable electronic assessment tool. A detailed account of its successor, the interRAI-HC assessment instrument, has been described previously \[[@CR16]\]. It includes 236 standardised questions analysing all aspects of an older person's life \[[@CR16]\]. Anyone requiring public funding for health services in New Zealand is required to undergo a needs assessment. An individual can be referred by health professionals such as their general practitioner, hospital-based professionals or community health workers. Generally, individuals requiring home care services are referred by a general practitioner or other health professional. A trained assessor visits the individual in their own home to conduct the home care assessment, the assessor spends time asking questions from the assessment, and items within the assessment include standardised responses with definitions and observational time periods. Assessors also refer to external health information such as patient records to ensure a complete and accurate picture of the individual's health at time of assessment \[[@CR15]\].

Using the recent Australian Frailty Index as a framework for our study, \[[@CR6]\] we aimed to develop and validate a frailty score for the Canterbury, New Zealand community dwelling older people using local MDS-HC data.

Methods {#Sec2}
=======

A regional longitudinal study was used to develop a frailty scale for older adults living in Canterbury, New Zealand. Outcome measures were mortality and entry into aged residential care (ARC) over a 5-year period. All data were anonymised. Ethics permission was granted by the New Zealand Ministry of Health and Disability Ethics Committee (14/STH/140).

Participants included 5586 community dwelling older people who had a MDS-HC assessment completed between 2008 and 2012, while living in the Canterbury province of New Zealand.

The MDS-HC is a standardised, geriatric, home care assessment consisting of over 200 questions, which are used to guide individual care planning. Assessments are conducted by trained assessors and each assessment is recorded electronically. Assessors visit the patient in person and ask questions, perform physical assessments and use up to date medical records.

Answers to 42 questions from the MDS-HC assessment were selected as variables in this study. The criteria for variable deficits from a recent Australian study were used in the selection of these variables \[[@CR6]\]. Variables were recoded into deficits as described in the supplementary section. Most of the questions used in the frailty index were recorded on a binary scale of 0 or 1 where 1 represents the presence of the deficit and 0 represents the absence. For example, when a person's memory was assessed, it was recorded as 0 = Memory is fine or 1 = Memory problem. These variables were directly translated into deficits. For ordinal and continuous variables, the answers were generally graded into deficits between 0 and 1, such as 0, 0.5, and 1. Thirty-eight of the 42 original variables were directly recoded into 38 potential deficits, while four variables had weightings on their deficit score. Three potential deficits were assigned to "behavioural symptoms", "number of falls", and "number of medications", and 15 for "count of disease diagnosis". This created a maximum score of 62. See Additional file [1](#MOESM1){ref-type="media"} for the list of diseases in the interRAI-MDS.

The frailty index was calculated by summing the number of deficits recorded for a patient and dividing by the total number of possible deficits. This created a frailty index with a potential range from 0 to 1. In instances where data was missing, the frailty index was calculated with an appropriately reduced denominator, so for example if a person was missing data for one item the maximum score was reduced to 61. Anyone with a denominator of less than 30 was omitted from the study. In this study, there were no missing variables, the entire cohort had a denominator of 62.

For comparative purposes, the 0--1 frailty index was recoded into a 6-point frailty scale, where each person was allocated a score between 0 and 5 with 0 being the least frail and 5 being the frailest (Table [1](#Tab1){ref-type="table"}). The scores on the scale correspond to the index as follows: Frailty Scale FS 0 having 0 ≤ FI \< 0.1, FS 1 having 0.1 ≤ FI \< 0.2, FS 2 having 0.2 ≤ FI \< 0.3, FS 3 having 0.3 ≤ FI \< 0.4, FS 4 having 0.4 ≤ FI \< 0.5, and FS 5 having FI ≥ 0.5.Table 1Frailty index rangesFailty index ranges0-0.990.1-0.190.2-0.290.3-0.390.4-0.49≥ 0.5Frailty scale012345Total\^ (%)391 (7.0)1960 (35.1)1993 (35.7)877 (15.7)287 (5.1)78 (1.4)Female^\*^ (%)198 (50.6)1191 (60.8)1265 (63.5)551 (62.8)178 (62)45 (58)Male^+^ (%)193 (49.4)769 (39.2)728 (36.5)326 (37.2)109 (38)33 (42)Mean age80.581.282.283.683.083.9^\^^Total people = 5586; ^\*^total female = 3428 (61%); ^+^total male = 2158 (38.1%)

Dates of death were provided by the New Zealand Births, Deaths and Marriages dataset and matched to encrypted unique national identifier numbers. The NHI or National Health Index number is the unique person identifier used throughout the New Zealand public health system. Residential care entry date was obtained from the Contracted Care Payment System of the New Zealand Ministry of Health.

Normality of the results was tested using the Kolmogorov-Smirnov test. Kaplan--Meier curves were used to discern the relationships between the frailty scale and mortality and admission to residential care, after five years.

Results {#Sec3}
=======

The total sample consisted of 5586 Canterbury District Health Board (CDHB), New Zealand, MDS-HC assessments. Participants were aged between 65 and 101 years, with a mean age of 82 years (SD 8.6 years). Most were females (3428; 61.3%) and European New Zealanders (4837, 86.6%). Individuals appeared to be cognitively healthy overall, however, over half of participants (2870, 51.4%) experienced a decline in ADLs and the majority have 2 or more disease diagnoses. The mean age increased with frailty (Table [1](#Tab1){ref-type="table"}). Table [2](#Tab2){ref-type="table"} features a count of deficits used in creating the frailty index.Table 2Patient characteristicsVariable (Deficit score)Frequency (%)Cognitive skills for daily decision making 03631 (65.0) 0.51536 (27.5) 1419 (7.5)Short Term memory 03241 (58.0) 12345 (42.0)Procedural memory 04541 (81.3) 11045 (18.7)Worsening of decision making 04530 (81.1) 11056 (18.9)Agitated or disoriented 05262 (94.2) 1324 (5.8)Sudden or new onset/change in mental function 05448 (97.5) 1138 (2.5)Making self understood 04482 (80.2) 0.5987 (17.7) 1117 (2.1)Ability to understand others 04272 (76.5) 0.51169 (20.9) 1145 (2.6)Hearing 02812 (50.3) 0.52676 (47.9) 198 (1.8)Vision 04047 (72.4) 0.5953 (17.1) 1586 (10.5)Withdrawal from activities of interest 04849 (86.8) 0.5275 (4.9) 1462 (8.3)Repetitive anxious complaints, concerns 04783 (85.6) 0.5384 (6.9) 1419 (7.5)Sad, depressed 04351 (77.9) 0.5691 (12.4) 1544 (9.7)Behaviour Symptoms 05280 (94.5) 1203 (3.6) 272 (1.3) 331 (0.6)Changes in behaviour symptoms 05320 (95.2) 1266 (4.8)Changes in social functioning 03116 (55.8) 0.51688 (30.2) 1782 (14.0)Bathing 02530 (45.3) 0.51733 (31.0) 11323 (23.7)Personal hygiene 04411 (79.0) 0.5340 (6.1) 1835 (14.9)Dressing upper body 03922 (70.2) 0.51095 (19.6) 1569 (10.2)Dressing lower body 03621 (64.8) 0.51209 (21.6) 1756 (13.5)Indoor mobility 03362 (60.2) 0.52077 (37.2) 1147 (2.6)Outdoor mobility 02565 (45.9) 0.52282 (40.9) 1739 (13.2)Transfer 04848 (86.8) 0.5519 (9.3) 1219 (3.9)Toilet use 04749 (85.0) 0.5173 (3.1) 1664 (11.9)Bed mobility 05078 (90.9) 0.596 (1.7) 1412 (7.4)Eating 05186 (92.8) 0.5188 (3.4) 1212 (3.8)Mobility in home 04835 (86.6) 0.5339 (6.1) 1412 (7.4)Mode of locomotion 03777 (67.6) 0.5727 (13.0) 11082 (19.4)Activities of daily living (ADL) decline 02716 (48.6) 12870 (51.4)Bladder continence 03581 (64.1) 0.51165 (20.9) 1840 (15.0)Bowel continence 04817 (86.2) 0.5555 (9.9) 1214 (3.8)Disease diagnoses 0140 (2.5) 1603 (10.8) 21081 (19.4) 31335 (23.9) 41070 (19.2) 5666 (11.9) 6365 (6.5) 7201 (3.6) 877 (1.4) 932 (0.6) 109 (0.2) 117 (0.1)Falls 03297 (59.0) 12058 (36.8) 2127 (2.3) 3104 (1.9)Unsteady gait 02049 (36.7) 13537 (63.3)Pain frequency 01855 (33.2) 0.5717 (12.8) 13014 (54.0)Pain intensity 01875 (33.6) 0.5970 (17.4) 12741 (49.1)Character of pain 01910 (34.2) 0.51896 (33.9) 11780 (31.9)Morbid obesity 05477 (98.0) 1109 (2.0)Weight loss 04683 (83.8) 1903 (16.2)Swallowing 05057 (90.5) 0.5514 (9.2) 115 (0.3)Pressure ulcer 05387 (96.4) 1199 (3.6)Medications 0115 (2.1) 11057 (18.9) 22269 (40.6) 32145 (38.4)Congestive Heart Failure Not present4352 (77.9) Present157 (2.8) Present and treated1077 (19.3) Coronary Artery Disease Not present4227 (75.7) Present223 (4.0) Present and treated1136 (20.3) Hypertension Not present2775 (49.7) Present351 (6.3) Present and treated2460 (44.0)Alzheimer's Not present5375 (96.2) Present57 (1.0) Present and treated154 (2.8)Dementia other than Alzheimer's Not present5279 (94.5) Present98 (1.8) Present and treated209 (3.7)Parkinsonism Not present5328 (95.4) Present33 (0.6) Present and treated225 (4.0)Arthritis Not present3243 (58.1) Present533 (9.5) Present and treated1810 (32.4)Osteoporosis Not present4427 (79.3) Present212 (3.8) Present and treated947 (17.0)Any psychiatric diagnosis Not present4726 (84.6) Present160 (2.9) Present and treated700 (12.5)Urinary Tract Infection Not present5232 (93.7) Present47 (0.8) Present and treated307 (5.5)Cancer Not present4792 (85.8) Present116 (2.1) Present and treated678 (12.1)Diabetes Not present4643 (83.1) Present166 (3.0) Present and treated777 (13.9)Emphysema/COPD/Asthma Not present4431 (79.3) Present173 (3.1) Present and treated982 (17.6)

The frailty index had a mean of 0.27 (SD 0.12) and a range from 0.01 to 0.7. The index was not normally distributed (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Distribution of Frailty Index

The five-year mortality rate was 67.1% (*n* = 3747). The relationship between the frailty score and mortality was significant (χ^2^ (5) = 332.2; *P* \< 0.001). At five years, 25.1% (*n* = 98) of people with a baseline frailty of \< 0.1 had died compared with 28.2% (*n* = 22) of those with a frailty index of ≥0.5 (FS 5),(Fig. [2a](#Fig2){ref-type="fig"}).Fig. 2Survival Curves of **a** Mortality and Grouped Frailty, **b** Entry to ARC and Grouped Frailty

After five years 2670 (47.8%) of people had entered ARC. The relationship between the frailty index and admissions to residential care was also significant (χ^2^ (5) = 252.67; *P* \< 0.001). At five years, 43.7% (*n* = 171) of people with a baseline frailty index of \< 0.1 (FS 0) were still living at home, compared to 2.6% (n = 2) of those with a frailty index of ≥0.5 (FS 5),(Fig. [2b](#Fig2){ref-type="fig"}).

Discussion {#Sec4}
==========

In this study we demonstrated that a frailty index developed from the interRAI MDS-HC assessment was significantly associated with five-year admission to residential care and mortality.

An Australian study used interRAI (AC) data from 1418 older adults presenting to acute hospitals in Queensland and Victoria formed the basis of our study \[[@CR6]\].

This Australian study found a slightly higher mean frailty index (0.32; SD 0.14) than that of our work (0.27; SD 0.12) \[[@CR6]\]. This difference could reflect the different settings of both studies: acute hospital care versus community dwelling. However, both studies had a similar dose response relationship for predicting mortality.

A recent large UK study, which calculated 36 deficits from pre-existing primary care health records, developed an electronic frailty index with four validated levels of frailty in over 900,000 older people \[[@CR1]\]. Outcome measures over one-, three-, and five-year periods highlighted good predictive validity for emergency hospital admission, mortality, and nursing home admission. Survival rates were lower in our study than the UK study which could reflect our investigation's focus on more frail and vulnerable members of a community dwelling population, rather than the general older population. The UK study demonstrated that risk of hospitalisation and length of hospital stay increased incrementally with the degree of frailty.

Another study of community dwelling older people contextualised frailty scores against clinical descriptors, \[[@CR17]\] and found a mean FI of 0.27 for patients who were mildly frail, with limited dependence on others for instrumental activities of daily living. This is consistent with the findings of our study.

The MDS-HC assessment prepopulates the Change in Health, End Stage Disease (CHESS) score from 12 specific questions to create a 6 point score \[[@CR18]\]. Although it is a valuable tool, the CHESS score is a measure of a person's health instability rather than frailty and it focuses on recent changes in an individual's health and level of function and does not include longer term indicators of frailty such as comorbidities and baseline activities of daily living (ADL) function. The larger number of potential deficits in our score allows for the identification of modifiable components which could be targeted to improve outcomes for individuals, such as exercise, nutrition programmes, and medication reviews to help reduce the effects of polypharmacy \[[@CR7]\].

There are a number of other validated frailty scales, \[[@CR1], [@CR9], [@CR19]\] but a significant advantage of our study and its utilisation of MDS-HC data, is that it allows for a comprehensive multi-dimensional perspective that aims to capture the complex nature of frailty without the need for further time consuming assessment. Furthermore, the fact that the interRAI suite of assessment tools are used over a number of different health settings means that individual levels of frailty using a standardised frailty index can be recorded both over time and across a variety of settings.

We acknowledge however, that this study utilised data from one region in New Zealand and that it may not be generalisable beyond this region. Additional work using this data set at a national level may be useful in identifying any ethnic differences in regard to frailty. Further work using New Zealand's national MDS-HC dataset will assist in understanding this index's generalisability including predicting other outcomes such as number and length of hospital admissions. We did not differentiate between frail individuals living at home or receiving daily care from those who live alone, and acknowledge that outcomes may have been poorer for the latter individuals.

Conclusion {#Sec5}
==========

A frailty index was developed from Canterbury's MDS-HC assessment data. From the index an easy to use scale was developed which could aid clinicians identify older people at risk of health decline and mortality. Frailty is not an inevitable part of ageing and nor should it be a barrier to interventions. It has the potential to be addressed and the individual's outlook improved if it is identified early enough and the appropriate healthcare investigations, or services are initiated.
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